Lymphoma & Myeloma has ended

Create Your Own Event

Lymphoma & Myeloma

10:30am PDT

Welcome TBAMorton Coleman, MD

10:35am PDT

Introduction to acute leukemia & hematologic malignancies session TBAGail Roboz, MD

10:40am PDT

Session I: Acute Leukemias (Part of this session is supported by an unrestricted educational grant through AbbVie, Inc.) Empire Ballroom WestGail Roboz, MD

10:41am PDT

Pre-session audience survey Empire Ballroom West

10:50am PDT

Diagnosis and treatment of newly diagnosed ALL Empire Ballroom EastPinkal Desai, MD

11:10am PDT

Immunotherapy of ALL Empire Ballroom EastPinkal Desai, MD

11:30am PDT

Which patients should be transplanted for ALL? Empire Ballroom EastKoen vanBesien, MD, PhD

12:00pm PDT

Panel discussion and post-session audience survey Empire Ballroom East

12:15pm PDT

Lunch Empire Ballroom West

1:45pm PDT

Session II: MPN & MDS Empire Ballroom EastGail Roboz, MD

1:46pm PDT

Pre-session audience survey Empire Ballroom East

1:55pm PDT

Monitoring patients on longstanding TKI therapy for CML: What to look for other than BCR-ABL Empire Ballroom EastEllen Ritchie, MD

2:15pm PDT

Treatment strategies for myelofibrosis Empire Ballroom EastEllen Ritchie, MD

2:35pm PDT

MDS: Is your hypomethylator working? Empire Ballroom EastSangmin Lee, MD

2:55pm PDT

Which patients with CML should stop TKI therapy? Empire Ballroom EastEllen Ritchie, MD

3:25pm PDT

Panel discussion and post-session audience survey Empire Ballroom East

3:40pm PDT

Break Empire Ballroom West

4:00pm PDT

Session III: Special Topics (Part of this session is supported by an unrestricted educational grant through AbbVie, Inc.) Empire Ballroom EastGail Roboz, MD

4:01pm PDT

Pre-session audience survey Empire Ballroom East

4:10pm PDT

Newly diagnosed AML: Hitting the right target Empire Ballroom EastGail Roboz, MD

4:30pm PDT

AML: What to do with your 500-gene mutation report Empire Ballroom EastSangmin Lee, MD

4:50pm PDT

MRD in AML: What is it and what do I do about it? Empire Ballroom EastGail Roboz, MD

5:10pm PDT

AML 60-80 years: Who should get an allo transplant? Empire Ballroom EastKoen vanBesien, MD, PhD

5:30pm PDT

Panel discussion and post-session audience survey Empire Ballroom East

8:00am PDT

Welcome Metropolitan Ballroom EastMorton Coleman, MD

8:05am PDT

Introduction to myeloma session Metropolitan Ballroom EastRuben Niesvizky, MD

8:10am PDT

Session IV: Precision Medicine in Myeloma (Part of this session is supported by an unrestricted educational grant through Adaptive Biotechnologies) Metropolitan Ballroom EastSuzanne Lentzsch, MD, PhD

8:11am PDT

Pre-session audience survey Metropolitan Ballroom East

8:20am PDT

Genomics 101: From deep sequencing to liquid biopsies Metropolitan Ballroom EastSamir Parekh, MBBS

8:30am PDT

Session I: Updates in Multiple Myeloma Central Park WestJeremy Heinerich, PA-C

8:31am PDT

Welcome and introduction of nurse practitioners and physician assistants track Central Park WestMorton Coleman, MD

8:40am PDT

Nurse practitioners and physician assistants track overview Central Park WestJeremy Heinerich, PA-C Genomics 102: Clinical use for treatment Individualization; including double hit myeloma Metropolitan Ballroom EastJoseph Mikhael, MD, MEd, FRCPC

8:45am PDT

Pre-session audience survey Central Park West

8:55am PDT

Role of immunomodulating agents in multiple myeloma Central Park WestKaren Pekle, NP

9:00am PDT

MRD: Ready for prime time? Is MRD for novel agents the same as for transplantation? Metropolitan Ballroom EastAjai Chari, MD • C.Ola Landgren, MD, PhD

9:30am PDT

Session summary Metropolitan Ballroom EastSuzanne Lentzsch, MD, PhD

9:40am PDT

Panel discussion and post-session audience survey Metropolitan Ballroom East

9:55am PDT

Break Central Park West Break Metropolitan Ballroom East

10:10am PDT

Role of transplant in multiple myeloma Central Park WestDaniel Verina, NP

10:30am PDT

Session V: Immuno-Oncology Metropolitan Ballroom EastHearn Jay Cho, MD, PhD

10:31am PDT

Pre- session audience survey Metropolitan Ballroom East

10:40am PDT

Vaccination as a therapeutic approach in myeloma Metropolitan Ballroom EastDavid Avigan, MD

11:00am PDT

Anti CD38, SLAMF-7 and BiTE immunotherapy: Are immune therapeutics ready for the frontline? Metropolitan Ballroom EastAlexander Lesokhin, MD

11:10am PDT

Interpretation of bone marrow biopsies in hematologic malignancies Central Park WestAmy Chadburn, MD

11:20am PDT

CAR-T: State of the art and perspective of a possible cure Metropolitan Ballroom EastAdam Cohen

11:40am PDT

Debate: Is allotransplant relevant today in myeloma? Metropolitan Ballroom EastSergio Giralt, MD • Shaji Kumar, MD

12:10pm PDT

Post-session audience survey Central Park West Panel discussion and post-session audience survey Metropolitan Ballroom East

12:30pm PDT

Lunch Empire Ballroom

2:00pm PDT

Session VI: Treatment I Metropolitan Ballroom EastAdriana Rossi, MD

2:01pm PDT

Precursor disorders in myeloma, can we cure some? Metropolitan Ballroom EastMaria-Victoria Mateos, MD, PhD

2:20pm PDT

Management of the fit patient: Induction, which one to choose, 3 or 4 drugs Metropolitan Ballroom EastAdriana Rossi, MD

2:40pm PDT

Management of the unfit and frail patient Metropolitan Ballroom EastCara Rosenbaum, MD

3:00pm PDT

Session summary Metropolitan Ballroom EastAdriana Rossi, MD

3:10pm PDT

Panel discussion Metropolitan Ballroom East

3:20pm PDT

Break Metropolitan Ballroom East

3:50pm PDT

Session VII: Special Lectures (Part of this session is supported by an unrestricted educational grant through Amgen, and Takeda Oncology) Metropolitan Ballroom EastRuben Niesvizky, MD • Morton Coleman, MD

3:51pm PDT

Pre-session audience survey Metropolitan Ballroom East

3:55pm PDT

Best myeloma abstract presentation Metropolitan Ballroom East

4:05pm PDT

New horizons in the treatment of relapsed and refractory myeloma Metropolitan Ballroom EastKenneth Anderson, MD

4:25pm PDT

The SASS foundation for medical research award: Michaeli Award for Contribution to Myeloma Metropolitan Ballroom EastMorton Coleman, MD • Ruben Niesvizky, MD • Jesus SanMiguel, MD • Maria-Victoria Mateos, MD, PhD

4:30pm PDT

Keynote Lecture: Is myeloma curable? Metropolitan Ballroom EastJesus SanMiguel, MD

5:00pm PDT

Panel discussion and post-session audience survey Metropolitan Ballroom East

8:00am PDT

Welcome Metropolitan Ballroom EastMorton Coleman, MD

8:05am PDT

Introduction to CLL Session Metropolitan Ballroom EastRichard Furman, MD

8:10am PDT

Session VIII: Small Molecule Inhibitors (Part of this session is supported by an unrestricted educational grant through AstraZeneca, Pharmacyclics, Inc., and Verastem Oncology) Metropolitan Ballroom EastRichard Furman, MD

8:11am PDT

Pre-session audience survey Metropolitan Ballroom East

8:20am PDT

Update on BTK inhibitors: Ibrutinib pus the new kids on the block: Are they better? Metropolitan Ballroom EastJohn Byrd, MD

8:40am PDT

Update on PI3K inhibitors: Idelalisib, copanlisib, duvelisib, umbralisib: Is toxicity the key? Metropolitan Ballroom EastJennifer Brown, MD, PhD

9:00am PDT

Update on venetoclax: How low can you go (MRD)? Metropolitan Ballroom EastRichard Furman, MD Session II: Updates in CLL Central Park WestJeremy Heinerich, PA-C

9:01am PDT

Welcome and introduction of nurse practitioners and physician assistants track Central Park WestMorton Coleman, MD

9:10am PDT

Nurse practitioners and physician assistants track overview Central Park WestJeremy Heinerich, PA-C

9:15am PDT

Pre-session audience survey Central Park West

9:20am PDT

Panel discussion and post-session audience survey Metropolitan Ballroom East

9:25am PDT

Managing toxicities of oral therapies in CLL Central Park WestJennifer Santamala, PharmD, BCOP

9:40am PDT

Break Metropolitan Ballroom West

10:10am PDT

Session IX: The Future of CLL (Part of this session is supported by an unrestricted educational grant through AstraZeneca, Pharmacyclics, Inc., and Verastem Oncology) Metropolitan Ballroom EastKanti Rai, MD

10:11am PDT

Pre-session audience survey Metropolitan Ballroom East

10:20am PDT

Update on chemotherapy in 2018. Is chemotherapy passé? Metropolitan Ballroom EastMitchell Smith, MD, PhD

10:25am PDT

Break Central Park West

10:40am PDT

Treatment options for the young patient with deletion 17p: Do they need a different approach? Metropolitan Ballroom EastNeil Kay, MD

10:45am PDT

Role of MRD negativity in CLL Central Park WestEmilee Thomas, PA-C

11:00am PDT

Prince Family Lecture: Changing treatment paradigm for CLL over the years Metropolitan Ballroom EastKanti Rai, MD

11:20am PDT

Gebroe Family Lecture: Can we predict who will get Richter’s transformation Metropolitan Ballroom EastDavide Rossi, MD

11:40am PDT

Panel discussion and post-session audience survey Metropolitan Ballroom East

11:45am PDT

Post-session audience survey Central Park West

12:00pm PDT

Lunch Empire Ballroom

1:30pm PDT

Session X: Special Topics in CLL Metropolitan Ballroom EastJacqueline Barrientos, MD

1:31pm PDT

Ethnic, environmental, genetic, and familial risk factors for CLL Metropolitan Ballroom EastSusan Slager, MD

1:50pm PDT

Next generation sequencing for the clinical oncologist: Demystifying the genomics black box Metropolitan Ballroom EastAndrew Lipsky, MD

2:10pm PDT

Bruce Waterfall Memorial Lecture: What are the best front-line therapies for Waldenström macroglobulinemia? Metropolitan Ballroom EastJorge Castillo, MD

2:30pm PDT

Break Metropolitan Ballroom East

3:00pm PDT

Pre-session audience survey Metropolitan Ballroom East Session XI: CLL Transformation Metropolitan Ballroom EastJohn Allan, MD

3:05pm PDT

What's next in CLL? Metropolitan Ballroom EastRichard Furman, MD

3:25pm PDT

Therapeutic options for Richter’s syndrome Metropolitan Ballroom EastJohn Allan, MD

3:45pm PDT

The sequencing of novel agents: Does it matter? Metropolitan Ballroom EastPeter Hillmen, MB ChB, PhD

4:05pm PDT

Panel discussion and post-session audience survey Metropolitan Ballroom East

7:35am PDT

Welcome Metropolitan Ballroom EastMorton Coleman, MD

7:40am PDT

Session XIII: Special Topics in Lymphoma I (Part of this session is supported by an unrestricted educational grant through AstraZeneca, and Celgene Corporation) Metropolitan Ballroom EastJohn Leonard, MD

7:41am PDT

Pre-session audience survey Metropolitan Ballroom East

7:45am PDT

What does the future hold with CAR-T cell therapy? Future constructs and indications, combinations and supportive care Metropolitan Ballroom EastCaron Jacobson, MD

8:05am PDT

BTK Inhibitors in B-Cell Malignancies: Opportunities and challenges Metropolitan Ballroom EastNancy Bartlett, MD

8:25am PDT

New antibodies and antibody-drug conjugates for B-cell lymphoma Metropolitan Ballroom EastAnas Younes, MD

8:45am PDT

Panel discussion and post-session audience survey Metropolitan Ballroom East

9:00am PDT

Welcome and introduction of nurse practitioners and physician assistants track Central Park WestMorton Coleman, MD Session XIV: Special Topics in Lymphoma II (Part of this session is supported by an unrestricted educational grant through Celgene) Metropolitan Ballroom EastGiorgio Inghirami, MD Session III: Hands-On Workshops in Lymphoma Central Park WestJeremy Heinerich, PA-C

9:01am PDT

Introduction to Lymphoma Session Metropolitan Ballroom EastJohn Leonard, MD

9:05am PDT

Pre-session audience survey Metropolitan Ballroom East Nurse practitioners and physician assistants track overview Central Park WestJeremy Heinerich, PA-C

9:10am PDT

Patient-derived xenografts (PDX) in lymphoma: How can they help advance therapy? Metropolitan Ballroom EastGiorgio Inghirami, MD Bone marrow biopsy workshop Central Park WestJeremy Heinerich, PA-C

9:30am PDT

New targets and tools in lymphoma treatment Metropolitan Ballroom EastLeandro Cerchietti, MD

9:50am PDT

Auto-transplant vs CAR-T: How should we sequence the therapy; who should receive therapy? Metropolitan Ballroom EastCaron Jacobson, MD

10:10am PDT

Panel discussion and post-session audience survey Metropolitan Ballroom East Lumbar puncture workshop Central Park WestJeremy Heinerich, PA-C

10:25am PDT

Break Metropolitan Ballroom East

10:45am PDT

Session XV: New Directions in Lymphoma Metropolitan Ballroom EastPeter Martin, MD

10:46am PDT

Pre-session audience survey Metropolitan Ballroom East

10:50am PDT

Debate: What is the best upfront approach for the treatment of Advanced Stage Hodgkin Lymphoma? Side 1: A (Brentuximab Vedotin) VD Metropolitan Ballroom EastNancy Bartlett, MD • Andrew Evens, DO, MSc

11:10am PDT

Break Central Park West

11:20am PDT

Debate: Is obinutuzumab superior to rituximab in lymphoma? Metropolitan Ballroom EastSonali Smith, MD • Jonathon Cohen, MD, MS

11:30am PDT

CAR T-cell in lymphoma Central Park WestRita Jakubowski, NP

11:50am PDT

Vitamin D in lymphoma therapy: What is its role and should we supplement? Metropolitan Ballroom EastJonathan Friedberg, MD

12:10pm PDT

Panel discussion and post-session audience survey Metropolitan Ballroom East

12:25pm PDT

Session XVI: Immunotherapy in Lymphoma Metropolitan Ballroom EastMorton Coleman, MD

12:26pm PDT

Pre-session audience survey Metropolitan Ballroom East

12:30pm PDT

Best lymphoma abstract presentation Metropolitan Ballroom East Hodgkin's lymphoma updates Central Park WestNadia Kralovic, PA-C

12:40pm PDT

The SASS Foundation for Medical Research Award Ceremony: John Ultmann Award for Contributions to Lymphoma Metropolitan Ballroom EastMorton Coleman, MD • Caron Jacobson, MD • Margaret Shipp, MD

12:50pm PDT

Keynote Lecture: Immunotherapy of Hodgkin’s and non-Hodgkin’s lymphoma Metropolitan Ballroom EastMargaret Shipp, MD

1:20pm PDT

Discussion and post-session audience survey Metropolitan Ballroom East

1:35pm PDT

Lunch Metropolitan Ballroom East

3:05pm PDT

Pre-session audience survey New York Ballroom West Session XVII: Follicular and Mantle Cell Lymphoma (Part of this session is supported by an unrestricted educational grant through Bayer Pharmaceuticals, MEI Pharma, and Verastem Oncology) New York Ballroom WestJohn Leonard, MD

3:10pm PDT

New data on upfront and maintenance therapy in follicular lymphoma New York Ballroom WestJohn Leonard, MD

3:30pm PDT

How I approach early relapsing follicular lymphoma Metropolitan Ballroom WestPeter Martin, MD

3:50pm PDT

How I approach the initial treatment of mantle cell lymphoma New York Ballroom WestJonathon Cohen, MD, MS

4:10pm PDT

Novel agents and approaches for mantle cell lymphoma New York Ballroom WestPeter Martin, MD

4:30pm PDT

How should we treat double hit and double expressor DLBCL New York Ballroom WestSarah Rutherford, MD Session XVIII: Aggressive and T-Cell Lymphoma New York Ballroom WestLisa Roth, MD

4:50pm PDT

New drugs for aggressive B cell lymphoma New York Ballroom WestAnas Younes, MD

5:10pm PDT

New developments in primary and secondary CNS lymphoma: Prevention and treatment New York Ballroom WestJames Rubenstein, MD, PhD

5:30pm PDT

Novel approaches for T cell lymphoma New York Ballroom WestJia Ruan, MD

5:50pm PDT

Post-session audience survey New York Ballroom West